Therapies

Our dedication
to R&D

Home /Therapies
Therapies
Kedrion Biopharma’s line of plasma-derived therapies is broad and diverse. With products to treat or prevent many rare diseases and conditions from hemolytic disease of the fetus and newborn to immune deficiencies to hemophilia, Kedrion Biopharma offers a wide and expanding array of treatments and therapies. (Update June 2025)
Therapeutic areas
Browse areas and view all products related to
Select area
STANDARD IMMUNOGLOBULINS
HUMAN ALBUMIN
COAGULATION FACTORS AND OTHER COAGULATION-RELATED PLASMA PROTEINS
HYPERIMMUNE IGS

STANDARD IMMUNOGLOBULINS

GAMMAKED

Human normal i.v. Immunoglobulin 10%

View product website

GAMMAPLEX

Human normal i.v. Immunoglobulin 10%

View product website

QIVIGY

Human normal i.v. Immunoglobulin 10%

View product website

YIMMUGO

Human normal i.v. Immunoglobulin 10%

View product website

HUMAN ALBUMIN

ALBUKED

Human Albumin solution

View product website

ALBUMINEX

Human Albumin solution

View product website

KEDBUMIN

Human Albumin solution

View product website

COAGULATION FACTORS AND OTHER COAGULATION-RELATED PLASMA PROTEINS

COAGADEX

Human coagulation
Factor X

View consumer website View provider website

KOĀTE

Human coagulation
Factor VIII

View product website

RYPLAZIM

Plasma-derived human
Plasminogen

View consumer website View provider website

HYPERIMMUNE IGS

KEDRAB

Human Rabies Immunoglobulin

View product website

RHOGAM

Human Anti D Immunoglobulin

View product website
NEWS

Discover our press releases, resources, events and stay updated on the latest news

Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients 21-03-2025 Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients Read the news
FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim® 20-11-2024 FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim® Read the news
Kedrion and Biotest Finalize Yimmugo Commercialization for US 02-10-2024 Kedrion and Biotest Finalize Yimmugo Commercialization for US Read the news